MedTrace Logo

Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix

NCT00430144 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2012-04-26

No results posted yet for this study

Summary

-list item one, The purpose of this study is to evaluate the overall response rate of belotecan (CKD-602) in recurrent or progressive carcinoma of uterine cervix

Conditions

Interventions

DRUG

Belotecan(CKD-602)

Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle

Sponsors & Collaborators

  • Sokbom Kang

    lead OTHER_GOV

Principal Investigators

  • Sokbom Kang · National cancer cencer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-08-31
Completion
2010-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00430144 on ClinicalTrials.gov